Navigation Links
Cynvec to Present at The 2009 New York Venture Summit
Date:6/15/2009

- Company Selected as a Top Innovator -

NEW YORK, June 15 /PRNewswire/ -- Cynvec LLC, a privately held biotechnology company focused on developing novel cancer therapies that harness the apoptotic ability of the sindbis viral vector, today announced that Frank Stonebanks, President and Chief Executive Officer, will present at The 2009 New York Venture Summit on Wednesday, June 17, 2009 at 3:00 p.m. eastern, in New York City.

Cynvec is one of 50 companies from the life sciences, technology and cleantech sectors to be selected as a Top Innovator and chosen to present at this conference which features early stage and emerging companies. Additional information about the conference can be found at: www.youngstartup.com

About Cynvec LLC

Cynvec, a privately held biotechnology company, is developing proprietary cancer therapies based on the apoptotic sindbis oncolytic viral vector, a novel technology that targets the over expressed laminin receptor on the surface of many solid tumors without affecting normal cells. Under an exclusive worldwide license from the NYU School of Medicine, Cynvec is developing its lead product, CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and pancreatic cancer as both a single agent and in combination with licensed chemotherapies. Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real time cancer diagnostic. Cynvec expects to begin Phase I clinical trials of CYN 101 in the third quarter of 2009. The sindbis vector has demonstrated in vivo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor, which is implicated in Alzheimer's disease, multiple sclerosis and Parkinson's. Further information on Cynvec can be found at www.cynvec.com.


'/>"/>
SOURCE Cynvec LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
2. Cynvec LLC(SM) to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
3. Cynvec LLC(SM) to Present at the Cowen and Company 29th Annual Health Care Conference
4. Cynvec to Present at the BIO National Venture Conference
5. Cynvec to Present at New York Biotechnology Association 18th Annual Meeting
6. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Avicena Group to Present at Noble Financial Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group and the ... as other research and development initiatives for potential stem cell protocol management for 2016 ... Cells Group executives began meeting to establish a working agenda and foster initiatives to ...
(Date:4/26/2016)... ... April 27, 2016 , ... Cameron Cushman ... as an associate in the firm’s Intellectual Property practice group. , Clients turn ... patent applications. He has an electrical engineering and computer engineering background, and experience ...
(Date:4/26/2016)... ... April 26, 2016 , ... Heidelberg Instruments, ... latest technology innovation for its Volume Pattern Generator (VPG) line of lithography systems. ... advanced photomasks as well as a solution for mid volume direct write lithography ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a biopharmaceutical research ... financing. Healthy investor interest drove significant oversubscription of the original $1.5M target. ... biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, Darryl ...
Breaking Biology Technology:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):